Founded in 2007 by Jan Steele and Dennis O’Brien, who will both continue to lead the business, Lucid Group provides medical education, medical communication, strategic consultancy and digital services to clients to drive better disease and patient management from offices in London, Beaconsfield and NYC.

With growth exceeding 30 per cent for the previous two years and a staff base of over 100 employees, Lucid has built strong, sustainable partnerships with many of the world’s leading Pharma companies.

The investment will enable Lucid to continue to build infrastructure to support this rapid growth, ensuring that its services and offerings remain of the highest quality. It will also enable stronger market presence in the US, where the business launched in 2016. In addition, the investment will support Lucid to build its digital and creative capability, to broaden support for clients.